Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company Drug

Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment

Fineline Cube May 5, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...

Company Drug

CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment

Fineline Cube May 5, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Drug

Fujian Cosunter Pharmaceutical Completes Enrollment in Phase II/III Trial for GST-HG171/Ritonavir

Fineline Cube May 5, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the completion of 1,200 patient...

Company

BeiGene Reports Q1 2023 Financial Growth, Advances Pipeline with Global Expansion Plans

Fineline Cube May 5, 2023

China-based BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has reported financial results for the...

Policy / Regulatory

China’s Regulatory Bodies Unveil Guidelines to Strengthen Supervision of Medical Aesthetic Industry

Fineline Cube May 5, 2023

The State Administration for Market Regulation, National Health Commission, National Administration of Traditional Chinese Medicine,...

Company Deals

Medisan Pharmaceutical Secures PPAR Agonist Technology from China Pharmaceutical University

Fineline Cube May 4, 2023

Harbin Medisan Pharmaceutical Co., Ltd (SHE: 002900) has announced a significant patent and technology transfer...

Company

Meihua International Medical Expands with New Healthcare Industrial Park in Hainan

Fineline Cube May 4, 2023

Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), has announced the acquisition of a land...

Company Drug

Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial

Fineline Cube May 4, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its first-in-class, once-daily oral fatty acid...

Company Drug

BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial

Fineline Cube May 4, 2023

Shanghai BDgene Technology Co., Ltd has announced that it has received tacit clinical trial approval...

Company Drug

SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301

Fineline Cube May 4, 2023

SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion...

Company Drug

Qilu Pharmaceutical Launches First Generic Iressa in the US Market

Fineline Cube May 4, 2023

China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...

Company Deals

NeuExcell Therapeutics Secures Over $14.5 Million in Pre-Series A+ Funding for Neurological Treatments

Fineline Cube May 4, 2023

NeuExcell Therapeutics, a Sino-US biotech company specializing in treatments for neurological damage and degenerative diseases,...

Company Drug

Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study

Fineline Cube May 4, 2023

Transcenta Holding Limited (HKG: 6628), a China-based biopharmaceutical company, has announced the completion of enrollment...

Company Drug

TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases

Fineline Cube May 4, 2023

Shanghai-based TYK Medicines has announced that it has received the green light from the Center...

Policy / Regulatory

NMPA Transitions Desloratadine, Loratadine, Ambroxol, and Naproxen to OTC Status

Fineline Cube May 4, 2023

The National Medical Products Administration (NMPA) has indicated on its website that four products will...

Company Drug

Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies

Fineline Cube May 4, 2023

Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study...

Company Deals

Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies

Fineline Cube May 4, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in...

Policy / Regulatory

Chinese Authorities Launch Special Campaign to Combat Fraud in Medical Insurance

Fineline Cube May 4, 2023

The National Healthcare Security Administration, Supreme People’s Procurator, Ministry of Public Security, Ministry of Finance,...

Company Deals

Johnson & Johnson’s Kenvue IPO Raises USD 3.8 Billion, Marking Year’s Largest US IPO

Fineline Cube May 4, 2023

US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced the initial public offering...

Company

Full-Life Technologies Ltd to Establish GMP-Compliant Radiopharmaceutical Plant in Belgium’s Wallonie Region

Fineline Cube May 4, 2023

Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region...

Posts pagination

1 … 548 549 550 … 684

Recent updates

  • Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
  • Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
  • Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.